위암 : 시장 전망, 역학, 경쟁 구도 시장 예측 리포트(2025-2035년)

Gastric Cancer Market Outlook

Thelansis's "Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Gastric Cancer Overview

Gastric cancer is the fifth most commonly diagnosed cancer worldwide and the fifth leading cause of cancer-related death, with a notably higher prevalence in men. Its pathogenesis is complex and heavily influenced by environmental and infectious risk factors; while Helicobacter pylori infection is the primary driver of distal (non-cardia) gastric cancers, other contributors include high-salt diets, N-nitroso compound exposure, smoked foods, and smoking. Conversely, increased BMI, gastroesophageal reflux disease (GERD), and smoking are strongly associated with the rising incidence of adenocarcinomas of the proximal stomach and gastroesophageal junction (GEJ). Molecularly, fibroblast growth factors (FGFs) play a pivotal role by binding to their receptors (FGFRs), triggering downstream oncogenic signaling cascades. Specifically, the FGFR2b isoform is an emerging prognostic and predictive biomarker. FGFR2b protein overexpression occurs to some degree in up to 38% of advanced gastric cancers-with clinically actionable, high-level overexpression present in approximately 16% of cases-particularly in diffuse-type and scirrhous subtypes. FGFR2 gene amplification, which can occur independently of protein overexpression, is seen in about 5-10% of cases. Both alterations correlate with deeper invasion, infiltrative growth, and a poor prognosis, underscoring the critical importance of emerging targeted treatments like the FGFR2b-directed monoclonal antibody bemarituzumab.

Key Highlights

• In Germany, survival-adjusted prevalent Gastric Cancer cases are projected to increase from 120,844 in 2025 to 129,241 by 2035.
• Gastric cancer continues to impose significant clinical burden due to late-stage diagnosis.
• HER2-targeted therapies and immunotherapies are increasingly influencing treatment paradigms.
• Unmet need remains high in advanced and metastatic disease management.

Market Overview

• The Spain Gastric Cancer market is projected to grow from USD 220 million in 2025 to USD 580 million by 2035.
• Growth is supported by expanding biomarker testing and adoption of targeted oncology therapies.
• Pipeline therapies including ADCs and immunotherapy combinations are expected to accelerate market expansion.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp & Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome & Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences (Nanjing), Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)